{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T04:21:08Z","timestamp":1787718068053,"version":"build-2784847793"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"DOI":"10.1007\/s00417-026-07467-y","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T03:58:37Z","timestamp":1787716717000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Methotrexate as an adjunct to pars plana vitrectomy for the prevention and treatment of proliferative vitreoretinopathy in rhegmatogenous retinal detachment: A clinical study"],"prefix":"10.1007","author":[{"given":"Ehab","family":"Mohamed Elsayed Saad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazem","family":"Elbadry Mohammed Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherif A.","family":"Dabour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Alyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"7467_CR1","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.2147\/OPTH.S111893","volume":"10","author":"A Sadaka","year":"2016","unstructured":"Sadaka A, Sisk RA, Osher JM, Toygar O, Duncan MK, Riemann CD (2016) Intravitreal methotrexate infusion for proliferative vitreoretinopathy. Clin Ophthalmol 10:1811\u20131817","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"7467_CR2","doi-asserted-by":"publisher","first-page":"20554","DOI":"10.1038\/s41598-020-77254-0","volume":"10","author":"S Delgado-Tirado","year":"2020","unstructured":"Delgado-Tirado S, Amarnani D, Zhao G, Rossin EJ, Eliott D, Miller JB, Greene WA, Ramos L, Arevalo-Alquichire S, Leyton-Cifuentes D, Gonzalez-Buendia L (2020) Topical delivery of a small molecule RUNX1 transcription factor inhibitor for the treatment of proliferative vitreoretinopathy. Sci Rep 10(1):20554","journal-title":"Sci Rep"},{"key":"7467_CR3","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.survophthal.2024.03.007","volume":"69","author":"F Sabatino","year":"2024","unstructured":"Sabatino F, Banerjee P, MM KM (2024) Clinical therapeutics for proliferative vitreoretinopathy in retinal detachment. Surv Ophthalmol 69:508\u2013520","journal-title":"Surv Ophthalmol"},{"key":"7467_CR4","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1745-6215-14-42","volume":"14","author":"PJ Banerjee","year":"2013","unstructured":"Banerjee PJ, Woodcock MG, Bunce C, Scott R, Charteris DG (2013) A pilot study of intraocular use of intensive anti-inflammatory triamcinolone acetonide to prevent proliferative vitreoretinopathy in eyes undergoing vitreoretinal surgery for open globe trauma; the Adjuncts in Ocular Trauma (AOT) Trial: study protocol for a randomized controlled trial. Trials 14:42","journal-title":"Trials"},{"key":"7467_CR5","doi-asserted-by":"crossref","unstructured":"Bedoui Y, Guillot X, S\u00e9lambarom J, Guiraud P, Giry C, Jaffar-Bandjee MC et al (2019) Methotrexate an Old Drug with New Tricks. Int J Mol Sci. ;20","DOI":"10.3390\/ijms20205023"},{"key":"7467_CR6","unstructured":"Nabai L (2019) Efficacy of kynurenic acid and methotrexate in prevention of fibrosis. University of British Columbia"},{"key":"7467_CR7","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.2147\/OPTH.S342717","volume":"16","author":"MP Paroli","year":"2022","unstructured":"Paroli MP, Del Giudice E, Giovannetti F, Caccavale R, Paroli M (2022) Management Strategies of Juvenile Idiopathic Arthritis-Associated Chronic Anterior Uveitis: Current Perspectives. Clin Ophthalmol 16:1665\u20131673","journal-title":"Clin Ophthalmol"},{"key":"7467_CR8","doi-asserted-by":"publisher","first-page":"657","DOI":"10.18502\/jovr.v16i4.9756","volume":"16","author":"F Abdi","year":"2021","unstructured":"Abdi F, Mohammadi SS, Falavarjani KG (2021) Intravitreal Methotrexate. J Ophthalmic Vis Res 16:657\u2013669","journal-title":"J Ophthalmic Vis Res"},{"key":"7467_CR9","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1177\/24741264221135799","volume":"7","author":"MA McAllister","year":"2023","unstructured":"McAllister MA, Moore SM, Bullock B, Christoforidis JB (2023) Intraocular Methotrexate for the Treatment and Prevention of Proliferative Vitreoretinopathy: A Review. J Vitreoretin Dis 7:144\u2013153","journal-title":"J Vitreoretin Dis"},{"issue":"3","key":"7467_CR10","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/s41433-024-03503-5","volume":"39","author":"VT Toh","year":"2025","unstructured":"Toh VT, Gerard G, Tay ZQ, Chen J, Chew GW, Teoh CS (2025) Efficacy and safety of methotrexate in the treatment of proliferative vitreoretinopathy: a systematic review. Eye 39(3):460\u2013467","journal-title":"Eye"},{"key":"7467_CR11","doi-asserted-by":"crossref","unstructured":"Benner JD, Dao D, Butler JW, Hamill KI (2019) Intravitreal methotrexate for the treatment of proliferative vitreoretinopathy. BMJ open Ophthalmol 4(1)","DOI":"10.1136\/bmjophth-2019-000293"},{"issue":"3","key":"7467_CR12","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1177\/24741264251323305","volume":"9","author":"L Gibson","year":"2025","unstructured":"Gibson L, Nguyen A, Ridgeway J, Omar M, Purvis C, Shihab Y, Riemann CD, Franklin AJ (2025) Postoperative methotrexate to reduce reoperation rate and improve vision in patients with complex retinal detachments, advanced diabetic retinopathy, and trauma. J VitreoRetinal Dis 9(3):336\u2013342","journal-title":"J VitreoRetinal Dis"},{"key":"7467_CR13","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/s10792-024-03152-3","volume":"44","author":"IG Gurelik","year":"2024","unstructured":"Gurelik IG, Ozdemir HB, Acar B (2024) The effect of adjuvant Mitomycin C during vitrectomy on functional and anatomical outcomes in patients with severe diabetic tractional retinal detachment. Int Ophthalmol 44:210","journal-title":"Int Ophthalmol"},{"issue":"1","key":"7467_CR14","first-page":"7807596","volume":"2016","author":"S Di Lauro","year":"2016","unstructured":"Di Lauro S, Kadhim MR, Charteris DG, Pastor JC (2016) Classifications for proliferative vitreoretinopathy (PVR): an analysis of their use in publications over the last 15 years. J Ophthalmol 2016(1):7807596","journal-title":"J Ophthalmol"},{"issue":"3","key":"7467_CR15","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3928\/23258160-20230220-01","volume":"54","author":"A Ullah","year":"2023","unstructured":"Ullah A, Toth CA, Burnett HW, Butler JW, Levy JH, Benner JD (2023) Low-dose intravitreal methotrexate for proliferative vitreoretinopathy. Ophthalmic Surg Lasers Imaging Retina 54(3):139\u2013146","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"7467_CR16","doi-asserted-by":"crossref","unstructured":"Jahangir S, Jahangir T, Ali MH, Lateef Q, Hamza U, Tayyab H, Ali MH, Chaudhry QL (2021) Use of intravitreal methotrexate infusion in complicated retinal detachment for prevention of proliferative vitreoretinopathy in a pilot study. Cureus 13(8)","DOI":"10.7759\/cureus.17439"},{"key":"7467_CR17","doi-asserted-by":"publisher","first-page":"251584142210974","DOI":"10.1177\/25158414221097418","volume":"14","author":"N Hasan","year":"2022","unstructured":"Hasan N, Chawla R, Shaikh N, Kandasamy S, Azad SV, Sundar MD (2022) A comprehensive review of intravitreal immunosuppressants and biologicals used in ophthalmology. Therapeutic Adv Ophthalmol 14:25158414221097418","journal-title":"Therapeutic Adv Ophthalmol"},{"key":"7467_CR18","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1159\/000500271","volume":"242","author":"R Nourinia","year":"2019","unstructured":"Nourinia R, Borna F, Rahimi A, Jabbarpoor Bonyadi MH, Amizadeh Y, Daneshtalab A et al (2019) Repeated Injection of Methotrexate into Silicone Oil-Filled Eyes for Grade C Proliferative Vitreoretinopathy: A Pilot Study. Ophthalmologica 242:113\u2013117","journal-title":"Ophthalmologica"},{"key":"7467_CR19","doi-asserted-by":"crossref","unstructured":"Gibson L, Nguyen A, Ridgeway J, Omar M, Purvis C, Shihab Y et al (2025) Postoperative Methotrexate to Reduce Reoperation Rate and Improve Vision in Patients With Complex Retinal Detachments, Advanced Diabetic Retinopathy, and Trauma. J Vitreoretin Dis 24741264251323305","DOI":"10.1177\/24741264251323305"},{"key":"7467_CR20","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/s41433-024-03503-5","volume":"39","author":"VTR Toh","year":"2025","unstructured":"Toh VTR, Gerard G, Tay ZQ, Chen J, Chew GWM, Teoh CS (2025) Efficacy and safety of methotrexate in the treatment of proliferative vitreoretinopathy: a systematic review. Eye (Lond) 39:460\u2013467","journal-title":"Eye (Lond)"},{"key":"7467_CR21","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1007\/s00417-021-05206-z","volume":"259","author":"JA Roca","year":"2021","unstructured":"Roca JA, Yon-Mendoza A, Huam\u00e1n N, Wu L (2021) Adjunctive serial post-operative intravitreal methotrexate injections in the management of advanced proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol 259:2913\u20132917","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"7467_CR22","doi-asserted-by":"crossref","unstructured":"Kocak I, Sayin N, Bayramoglu SE, Thalib L (2025) Effect of methotrexate in preventing retinal detachment after proliferative vitreoretinopathy surgery: a systematic review and meta-analysis. Surv Ophthalmol.","DOI":"10.1016\/j.survophthal.2025.09.015"},{"key":"7467_CR23","doi-asserted-by":"publisher","first-page":"95","DOI":"10.51329\/mehdiophthal1452","volume":"11","author":"JH Fouad Aziz","year":"2022","unstructured":"Fouad Aziz JH, Abd Al-Hakim Zaki M, Abd El-Fattah El-Shazly A, Mamoun T, Abdel Ghaffar Helmy RO, Hashem MH (2022) Intravitreal methotrexate infusion for prophylaxis of proliferative vitreoretinopathy after pars plana vitrectomy for rhegmatogenous retinal detachment. Med Hypothesis Discov Innov Ophthalmol 11:95\u2013103","journal-title":"Med Hypothesis Discov Innov Ophthalmol"},{"key":"7467_CR24","unstructured":"Chaudhary R (2020) An investigation of vitreous biomarkers associated with proliferative vitreoretinopathy development. University of Birmingham"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-026-07467-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-026-07467-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-026-07467-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T03:58:39Z","timestamp":1787716719000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-026-07467-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":24,"alternative-id":["7467"],"URL":"https:\/\/doi.org\/10.1007\/s00417-026-07467-y","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"assertion":[{"value":"17 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"An informed written consent was obtained from all patients.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}